Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) just unveiled an announcement.
CK Life Sciences International (Holdings) Inc. has announced promising preclinical results for its novel cancer vaccines targeting TROP2, a protein overexpressed in various aggressive cancers. The vaccines have shown impressive tumor growth inhibition in mice studies, particularly in breast and colorectal cancers, and the company aims to advance these vaccines into clinical trials. The potential commercialization of these vaccines could bring significant economic benefits, although clinical trials have not yet commenced, and patent approvals are pending.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings) Inc. operates in the biotechnology industry, focusing on the development of cancer vaccines. The company is engaged in research and development of novel therapeutics, with a particular emphasis on targeting tumor antigens and immune checkpoint proteins.
YTD Price Performance: 17.07%
Average Trading Volume: 5,190,019
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.61B
For a thorough assessment of 0775 stock, go to TipRanks’ Stock Analysis page.